ArticlemAbs2026
Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancing antibody-dependent cellular cytotoxicity (ADCC) via N-glycan afucosylation of Asn-297 is a validated strategy to improve the clinical efficacy of therapeutic antibodies. However, the impact of distinct glycoengineering approaches on the function of antibodies has not been systematically elucidated. Here, we experimentally compared two type II anti-CD20 antibodies, Obinutuzumab (Gazyva®) and Obinutuzumab beta (MIL62, Bejescin®), which share identical amino acid sequences but exhibit divergent glycosylation profiles. MIL62 was engineered with complete core afucosylation (fucose < 0.1%) lacking bisecting N-acetylglucosamine (GlcNAc) via knockout of the GDP-fucose transporter (GFT) in Chinese hamster ovary (CHO) cells used to produce the antibody. Conversely, Gazyva was produced in CHO cells that overexpress β-1,4-N-acetylglucosaminyltransferase III (GnT-III) and α-mannosidase II (α-ManII), resulting in ~50% fucose content and >80% bisecting GlcNAc occupancy. These distinct glycoengineering strategies led to disparate functional outcomes: afucosylated MIL62 showed improved FcγRIIIA binding and ADCC potency, while Gazyva with bisecting GlcNAc modifications exhibited higher glycoform heterogeneity and reduced thermal stability. Both antibodies displayed comparable FcRn binding, mannosylation, sialylation, and murine pharmacodynamics, mediating complete depletion of B cells in blood, lymph nodes, and spleen. Upon antigen rechallenge, MIL62 suppressed specific antibody titers, indicating memory B-cell eradication and profound potential to prevent autoimmune relapse. This study demonstrates that distinct glycoengineering strategies fundamentally reshape the antibody glycan profile beyond merely reducing fucose. These structural differences not only fine-tune ADCC potency, but also impact antibody stability. Particularly, complete afucosylation of MIL62 led to optimized ADCC potency and effectively suppressed pathogenic B cells repopulation in a delta-like ligand 3 (DLL3) re-challenge model, providing a critical framework for designing next-generation antibodies with superior therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.